Whilst the outbreak of the latest strain of Coronavirus – Covid-19 – is a scare for healthcare systems and citizens worldwide, it presents an opportunity to pharma and government to reassess the way they work together.
Maurits Lugard, partner at Sidley Austin’s Life Sciences practice, and Anna-Shari Melin, associate at Sidley Austin write about the measures being put into place to prevent and manage medicinal product shortages in the EU.
Elizma Parry - director, Global Clinical Practice at Maetrics explains what pharmaceutical manufacturers should be doing to prepare for new and important regulations surrounding medical devices.
Life sciences firms owe it to themselves to capitalise on new global insights contained within the substantial new regulatory database systems they have had to build for compliance purposes, says Amplexor's David Gwyn.
Karen Rossington from Contec discusses how a new good manufacturing practice regulation is set to impact cleaning programmes within the pharmaceutical industry.
Automation is to play a key role in transforming regulatory processes in life sciences, but is AI being oversold by business process delivery partners? Alan White, CEO of Arriello, warns that focussed application is essential to delivering results.
Graham Francis, product marketing manager at Kallik writes about how new technologies are helping pharma companies keep up with changing labelling regulations.
